Kornimate/medical-research-clean huggingface dataset:
the effect of rpms on motor skill performance in persons with a stroke.

Conditions: Stroke

Summary: in the past two decades, even as stroke cases increase around the world, advances in motor rehabilitation have been limited. clinical trials of stroke rehabilitation have examined the therapeutic utility of several neuromodulatory devices to improve efficacy of motor training. however, there is limited knowledge on the effects of sensory-based priming techniques using repetitive peripheral magnetic stimulation (rpms) post stroke. this project focuses on understanding the effect of rpms on motor skill performance in persons with stroke.

the central hypothesis of this study is that rpms is a suitable priming technique for enhancing motor skill performance in individuals with stroke. the investigators plan to test our hypothesis by pursuing the following specific aim: to determine whether rpms can facilitate lower limb's motor skill performance more than sham rpms in individuals with stroke. hypothesis: the effect of stimulation on lower limb's motor skill performance will be measured using a visuomotor tracking task at different time points: baseline, immediately after, at 30 minutes, and 60 minutes after stimulation. individuals with stroke during the rpms condition will demonstrate greater motor skill performance following rpms and will be able to sustain the enhanced performance at 30 and 60 minutes after the stimulation, compared to sham condition. this study will improve our understanding of the effects of rpms, thus encouraging the use of a single session of rpms as a priming tool to enhance motor skill performance. the proposal is important as it is the first to study the time course effects of rpms on lower limb's motor skill performance in stroke populations.

Eligibility criteria:
inclusion criteria: * diagnosed mono-hemispheric stroke * more than 3 months since stroke onset. * participants must demonstrate adequate cognitive abilities to be able to follow the protocol (21\>mmse). exclusion criteria: * individuals with lesions affecting the brainstem or cerebellum. * other musculoskeletal or neurological impairments such as (alzheimer, parkinson, etc.). * complete paralysis that would limit the participant's' ability to perform motor skill tasks.

Keywords: rpms motor skill performance
copilot-hf: cooperative program for implementation of optimal therapy in heart failure

Conditions: Heart Failure

Summary: this is a randomized, open-label, initiative within the mass general brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (lvef).

the primary objectives are: 1. determine if a remote, or virtual, clinic that implements a standardized, stepped-approach to guideline-directed medication optimization in patients with heart failure (across the spectrum of ejection fraction), will achieve a higher rate of guideline-directed medical therapy (gdmt) than a strategy of patient and provider education followed by remote heart failure clinic management. 2. in eligible patients with lvef\<50%, determine if the sequencing of gdmt initiation (traditional vs. sodium-glucose co-transporter-2 inhibitors-first) leads to improved gdmt intensification

Eligibility criteria:
inclusion criteria: * documented diagnosis of heart failure (e.g., icd-9 codes 428 icd-10 codes i50 or problem list in the electronic health record) * most recent ef assessed within the past 24 months * seen mass general brigham provider within the last 24 months * english or spanish speaking exclusion criteria: * lvef\<50% currently prescribed or intolerant to both arni and sglt2i * lvef\>50% currently prescribed or intolerant to sglt2i * systolic blood pressure (sbp) \<90 mmhg at last measure * current severe aortic stenosis or severe aortic insufficiency * known amyloid heart disease * group 1 pulmonary arterial hypertension on disease-specific therapies (e.g., ambrisentan, bosentan, epoprostenol, treprostinil, iloprost) * egfr\<30 ml/min/1.73m2 * active chemotherapy * receiving end-of-life care or hospice * history of transplant, currently listed above status 4 or being evaluated for transplant * outpatient intravenous inotrope use * current use of a ventricular assist device * physician's discretion as inappropriate for remote management program
a study in healthy adult subjects to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of abt-333

Conditions: HCV Infection

Summary: the purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of abt-333 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state abt-333 pharmacokinetics

phase 1, blinded, randomized, placebo-controlled study in healthy adult subjects to evaluate the safety, tolerability, and pharmacokinetic profiles of multiple doses of abt-333

Eligibility criteria:
inclusion criteria: * main selection criteria for healthy volunteers: * subject has provided written consent. * subject is in general good health. * if female, subject is postmenopausal for at least 2 years or surgically sterile. * if female, subject is not pregnant and is not breast-feeding. * male or female between 18 and 55 years old, inclusive. * if male, subject must be surgically sterile or practicing at least 1 method of birth control. * body mass index (bmi) is 18 to 29, inclusive. exclusion criteria: * see above for main selection criteria
comparative study between conventional crystalloid cardioplegic solution with modified del nido cardioplegia

Conditions: Mitral Valve Surgery

Summary: mitral valvuloplasty for correction of chronic mitral regurgitation carries a lower operative mortality and morbidity and improved long-term survival than does mitral valve replacement. unfortunately, mitral valvuloplasty is not possible in all patients with chronic mitral regurgitation because of unfavorable pathology or lack of experience with this technique

cardioplegia is a fundamental component in providing heart protection, limiting metabolic activity and increasing the myocardium's capacity to resist ischemia for prolonged periods, thus being essential for good surgical outcomes. numerous cardioplegia solutions exist with different compositions to provide sufficient myocardial protection. however, there is no standard for the optimal or ideal composition and delivery technique. cardioplegia solutions are crystalloid or blood-based solutions with various chemical compounds. despite improvements in myocardial protection, prosthetic valves, surgical techniques, and postoperative care, the operative mortality and morbidity of mitral valve replacement for chronic mitral regurgitation remains high in comparison with other commonly performed heart operations. the timing of the administration of cardioplegia is extremely important in terms of preventing myocardial dysfunction. conventional multidose cardioplegias should be repeatedly administered in every 15 to 20 min. frequent interruption of the surgical process, even for a short time, before each cardioplegia delivery leads to a loss of time during open heart surgery, where time is extremely important, and disrupts the coherence of the operation and the surgical concentration. crystalloid cardioplegic solutions achieve cardioplegic arrest through inhibition of either fast-acting sodium channels or calcium-activated mechanisms. hyperkalemia can be used to inhibit the fast-acting sodium channels as it is in the st.thomas hospital solution and its modifications.

Eligibility criteria:
inclusion criteria: - patients scheduled for elective mitral regurge replacement surgery with normal coronaries exclusion criteria: 1. patients with chronic renal disease (previous medical diagnosis or serum creatinine greater than 1.5mg/dl) 2. left ventricular ejection fraction less than 50%. 3. previous cardiac surgery 4. patient with bmi \> 30 5. severe psychiatric illness 6. inability or unwillingness to give informed consent for participation
the safety and efficacy of median nerve electrical stimulation for improving neurological function prognosis in patients with cardiac arrest

Conditions: Median Nerve; Coma; Post Cardiac Arrest Brain Injury

Summary: median nerve stimulation (mns), a non-invasive brain stimulation technique, has been widely adopted in clinical arousal therapies and multiple clinical investigations have attested to the efficacy of this technique; nevertheless, evidence concerning the application of mns in improving the neurological prognosis of patients with return of spontaneous circulation (rosc) following cardiac arrest (ca) remains scarce. the current study endeavors to assess the safety and efficacy of mns treatment in enhancing the neurological prognosis of ca patients after rosc and it is designed as a multicenter, prospective, randomized controlled trial with an estimated sample size of 400 patients. eligible patients will be randomly allocated in a 1:1 ratio to either receive mns treatment or sham stimulation treatment for 8 hours per day for 14 consecutive days and the primary outcome measure is the proportion of patients in each group with a cerebral performance category (cpc) score ranging from 1 to 2, 6 months after randomization, which will help to determine the effectiveness of mns in providing neuroprotection for patients with rosc after ca.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. hemodynamics remains continuously stable for ≥ 7 days. 3. there is still a lack of purposeful movements after the return of spontaneous circulation following cardiopulmonary resuscitation. 4. advanced life support is provided within 6 hours after the return of spontaneous circulation (rosc). exclusion criteria: 1. patients with hemodynamic instability. 2. pregnant patients. 3. those who have abnormal anatomical structures on the median nerve conduction pathway and are unable to receive electrical stimulation. 4. patients with a confirmed history of epilepsy before admission or during hospitalization. 5. patients with severe arrhythmia or those who have pacemakers implanted. 6. patients whose family members do not agree to their enrollment in the study.
high resolution anuscopy study

Conditions: Human Papilloma Virus; Anal Squamous Cell Carcinoma

Summary: the majority of anal squamous cell carcinomas (scc) stem from infection with high-risk human papillomavirus (hpv). anal scc is rare among the general population but affects several populations disproportionately. high-risk groups are screened through anal swabs for anal cytology and detection of high risk human papillomavirus (hr hpv). hra referral is recommended for individuals with abnormal cytology. hra represents the only method to identify precancerous lesions of the anal canal, with only few specialists knowledgeable about it. at uz brussel, the investigators collected a wealth of data about hpv infection and its association with anal pathology. by establishing a comprehensive study, the investigators can delve into this data with specific research questions, conducting valuable research to provide answers to pressing clinical questions and contribute to advancements in medical understanding and treatment.


Eligibility criteria:
inclusion criteria: * all patients who have undergone hra and all future patients referred for hra in uz brussel * 18 years or older * understands and able to speak and write in french, dutch or english exclusion criteria: * none
filtered trial for amlodipine non-responder

Conditions: Hypertension

Summary: to demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.


Eligibility criteria:
inclusion criteria: 1. essential hypertensive patients satisfying all of the following criteria; 2. male or female 3. age \> 20 years 4. outpatient 5. patients who are able to stop current anti-hypertensive therapy at visit 1 if taking any anti-hypertensive medications 6. patients with an ability to provide written informed consent in accordance with the related laws and guidelines such as good clinical practice (gcp) and the pharmaceutical affairs law. exclusion criteria: 1. taking four or more anti-hypertensive medications 2. secondary hypertension 3. mean seated diastolic blood pressure (dbp) \> 114 mmhg and/or mean seated systolic blood pressure (sbp) \> 200 mmhg at visit 1, 2, 3, or 4, or mean seated dbp \< 90 mmhg at visit 3. 4. sustained ventricular tachycardia or other clinically relevant cardiac arrhythmias 5. congestive heart failure patients with the new york heart association (nyha) functional class iii-iv 6. history of myocardial infarction or cardiac surgery within last 6 months 7. history of coronary artery bypass graft or percutaneous coronary intervention (pci) within last 3 months 8. history of unstable angina within last 3 months 9. hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve 10. history of stroke or transient ischemic attack within last 6 months 11. history of sudden exacerbation of renal function with angiotensin ii receptor blockers (arbs) or angiotensin converting enzyme (ace) inhibitors, or patients with post-renal transplant or post-nephrectomy 12. experienced characteristic symptoms of angioedema during treatment with arbs or ace inhibitors 13. known hypersensitivity to any component of the investigational drug , or a known hypersensitivity to dihydropyridine -derived drugs 14. hepatic and/or renal dysfunction 15. diagnosed biliary atresia or cholestasis 16. hyperkalemia 17. dehydration 18. sodium deficiency 19. chronic administration of high doses of acidic nonsteroidal anti-inflammatory drugs (nsaids) 20. patients who cannot change to the restricted administration and dosage during study period 21. pre-menopausal women who meet any one of the following 1 - 3: * pregnant or possibly pregnant (1) * nursing (2) * desire to become pregnant during study period (3) 22. drug or alcohol dependency 23. complication of malignant tumour or a disease requiring immunosuppressants 24. compliance of \ 120% during the run-in period 25. receiving any investigational therapy within 3 months 26. judged to be inappropriate by the investigator or the sub-investigator
study of aztreonam for inhalation in children with cystic fibrosis and new infection of the airways by pseudomonas aeruginosa bacteria

Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization; Cystic Fibrosis

Summary: the primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (azli) in pediatric participants with new onset pseudomonas aeruginosa respiratory tract infection or colonization.


Eligibility criteria:
key inclusion criteria: * diagnosis of cystic fibrosis (cf) as determined by the 2008 cf consensus conference criteria: sweat chloride level ≥ 60 milliequivalents per liter (meq/l) by quantitative pilocarpine iontophoresis; or a genotype with 2 identifiable mutations consistent with cf; or an abnormal nasal transepithelial potential difference (npd), and 1 or more clinical features consistent with cf * documented new onset of positive respiratory tract culture for pa within 30 days of screening defined as either first lifetime documented pa-positive culture, or pa recovered after at least a 2-year history of pa-negative respiratory cultures (at least 2 cultures per year) * forced expiratory volume in one second (fev1) ≥ 80% predicted (for subjects ≥ 6 years of age who can reliably perform spirometry assessments) * clinically stable with no evidence of acute significant respiratory symptoms that would require administration of intravenous (iv) antipseudomonal antibiotics, oxygen supplementation, or hospitalization key exclusion criteria: * use of iv or inhaled antipseudomonal antibiotics within 2 years of screening * use of oral antipseudomonal antibiotics for a respiratory event within 30 days of study entry (screening visit) * history of intolerance to inhaled short acting β2 agonists * history of lung transplantation * current requirement for daily continuous oxygen supplementation or requirement of more than 2 l/minute at night * hospitalization for a respiratory event within 30 days prior to screening * changes in bronchodilator, corticosteroid, dornase alfa, or hypertonic saline medications within 7 days prior to screening. * significant changes (per investigators discretion) in physiotherapy technique or schedule within 7 days prior to screening * abnormal renal or hepatic function results at most recent test within the previous 12 months, defined as aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 5 times upper limit of normal (uln), or serum creatinine \> 2 times uln for age * presence of a condition or abnormality that would compromise the subject's safety or the quality of the study data, in the opinion of the investigator * known hypersensitivity to aztreonam, its metabolites, or formulation excipients in azli * respiratory cultures performed within 24 months prior to screening that are positive for any burkholderia spp. or non-tuberculous mycobacteria (ntm) note: other protocol defined inclusion/exclusion criteria may apply
study on the effect of external magnetic stimulation on patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this research study is to test the usefulness of external magnetic stimulation (ems) for treating the motor, cognitive, and neuropsychiatric symptoms of parkinson's disease (pd). participants with parkinson's disease will be recruited at the padrecc of the philadelphia va medical center. enrolled participants will be randomly assigned to receive either active external magnetic stimulation or fake stimulation. the external magnetic stimulation is delivered by wearing a helmet that is embedded with many small circuits which produce a very small magnetic field around the head. the helmet is to be worn daily for two minutes immediately before bedtime for three months in a row. the helmet is for investigational use only and has not been approved for use by the fda.

current research seeks to provide a drug-free, non-invasive and non-toxic therapy for parkinson's disease through transcranial magnetic stimulation (tms) in the form of picotesla magnetic therapy (ptmt). this therapy consists of an electronic device that emits magnetic flux densities that are more than ten million times lower than the magnetic flux density of the earth's magnetic field. repetitive transcranial magnetic stimulation (rtms) therapy aims to manipulate overall quality of life by improving motor function, as well as cognitive and neuropsychiatric symptoms such as depression.

Eligibility criteria:
inclusion criteria: * 40 to 80 years of age * diagnosis of possible or probable pd by the uk brain bank clinical diagnostic criteria * stable anti-parkinsonian medical regimen for at least 30 days prior to enrollment * hoehn \& yahr scale score of i to iii * no evidence of secondary or atypical parkinsonism on mri test in the past year * subjects are capable of giving informed consent exclusion criteria: * contraindications to mri (e.g. cardiac pacemaker, claustrophobia, metal fragments or hardware within the orbit or cranium) * history of stroke or tia within the past year * dementia defined as a mmse score \< 25 * status post deep brain stimulation surgery * unstable medical conditions that would likely prevent the subject from completing the study

Keywords: parkinson's disease transcranial magnetic stimulation
efficacy and safety of mcs-2 in the treatment of lower urinary tract symptoms

Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia

Summary: the hypothesis of the study is to examine whether mcs-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

eligible male subjects will be randomized to receive either mcs-2 or placebo for 12 weeks. subjects are those not currently on any medicines for bph or luts. during and at the end of the 12-week treatment period, randomized subjects will be evaluated for efficacy and safety parameters. all subjects will be advised to maintain a normal diet, similar to what was consumed before joining the study.

Eligibility criteria:
inclusion criteria: * age ≧ 40 years old. * not being treated for bph or luts. * psa ≦ 4 ng/ml and no pathologically-proven prostate cancer. * i-pss ≥ 10 * no known malignancy * ast/alt ≦ 3x unl. * creatinine ≦ 3x unl. * subjects who sign the informed consent form. exclusion criteria: * subjects' luts are not bph-related * have been treated with pelvis irradiation or pelvic surgery. * plan to undergo any invasive procedures within the study period. * active infection or inflammation. * considered ineligible by the investigators.

Keywords: benign prostatic hyperplasia multi-carotenoids mcs-2 lower urinary tract symptoms international prostate symptom scores
sexual dysfunction check-up in premenopausal breast cancer survivors taking endocrine therapy: a cross-sectional study

Conditions: Breast Cancer Female; Sexual Dysfunction; Premenopausal Breast Cancer

Summary: primary objectives: * to estimate sexual dysfunction (sd) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy. * to detect the presence of sd-related distress in the population, as a determining factor in the maintenance of a good quality of life. secondary objectives: * to describe sd characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens. * collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce sd prevalence in this population.


Eligibility criteria:
inclusion criteria: * women aged ≥18 and ≤ 55 * who underwent surgery for early stage breast cancer * taking endocrine therapy for at least 3 months * providing an informed consent and completing the study questionnaires. exclusion criteria: * withdrawal of the informed consent, at any time